MOLECULARMD provides innovative and reliable molecular diagnostics products and services to support clinical development, regulatory approval, and commercialization of targeted cancer therapies.

Using both gold-standard and innovative platforms, we design sensitive, specific, standardized assays that provide robust, reproducible results in an expeditious manner appropriate for decision-making by clinical investigators, sponsors, community physicians and patients.

At MolecularMD we are committed to accelerating the pace of targeted therapy development and personalizing medicine for cancer patients.

MolecularMD Announces Issuance of Patent Covering Methods for Therapeutic Resistance Monitoring in Lung Cancer Patients

Medco Partners with MolecularMD on Personalized Medicine Program for Chronic Myeloid Leukemia